[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 123
1. Colling R, Lopes T, Das N, Mathew J: Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma. BMJ Case Rep; 2010;2010
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma.
  • Metastasis to the uterine corpus is uncommon and secondary colorectal tumours of the endometrium are rare.
  • We describe a uterine tumour with components of both primary endometrial and metastatic colorectal carcinomata.
  • A transvaginal ultrasonography showed a thickened endometrium.
  • Histology immunophenotyping showed a CK7+, CK20+, CA125- and CEA+ colorectal metastasis (a profile consistent with her previous cancer) associated with a primary CK7+, CK20-, CA125+ and CEA- endometroid endometrial adenocarcinoma.
  • We conclude this represents endometrial metastasis of colorectal carcinoma with coincident primary endometrial adenocarcinoma.
  • We speculate as to whether the endometrial carcinoma arose de novo or was induced by the colorectal metastasis, or whether the primary endometrial tumour provided a fertile site for the colorectal metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Carcinoma, Endometrioid / diagnosis. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / pathology. Endosonography. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Apr;13(4):379-88 [10786803.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(2):122-6 [11446475.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] Jpn J Surg. 1991 May;21(3):352-6 [1857041.001]
  • [Cites] Pathologe. 1993 Jan;14(1):58-60 [8451231.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):383-6 [8804459.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):981-2 [10370650.001]
  • [Cites] Dis Esophagus. 2005;18(2):124-6 [16053489.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):101-20 [16633059.001]
  • [Cites] Surg Today. 2008;38(7):651-5 [18612793.001]
  • [Cites] APMIS. 2008 Jun;116(6):538-40 [18754330.001]
  • [Cites] Int J Surg Pathol. 2011 Dec;19(6):787-90 [19443868.001]
  • (PMID = 22791861.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3028565
  •  go-up   go-down


2. Boran N, Akdag D, Halici F, Tulunay G, Turan T, Bozok S, Erdogan Z, Kose MF: A retrospective analysis of the diameter of metastatic lymph nodes in apparently early stage endometrial cancer. Tumori; 2008 Sep-Oct;94(5):681-5
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of the diameter of metastatic lymph nodes in apparently early stage endometrial cancer.
  • AIMS AND BACKGROUND: The objective of this retrospective study was to assess the diameter of metastatic lymph nodes in a population of women with apparently early stage endometrial cancer at laparotomy.
  • METHODS AND STUDY DESIGN: Among 700 cases with endometrial cancer, 27 cases with disease clinically limited to the uterus in the laparotomy and found to have retroperitoneal node metastasis after pathologic examination were included in this study.
  • Pathologic characteristics of the tumors, pelvic and para-aortic node counts and the largest diameter of each metastatic node were evaluated.
  • A total of 85 metastatic nodes were identified.
  • Mean diameter of the metastatic para-aortic and pelvic nodes was 6.8 mm and 9 mm, respectively.
  • Nine patients had single metastatic nodes, and the diameters of the single metastatic para-aortic lymph node was 1 mm in one case, 2 mm in one case, 3 mm in one case and 4 mm in one, and 5 mm in two patients.
  • Diameters of the metastatic para-aortic lymph nodes were 4 and 5 mm in one case and 4 mm in the other case.
  • CONCLUSIONS: The diameters of metastatic nodes may be as small as 1 mm.
  • For correct staging of cases with endometrial cancer, complete systematic para-aortic and/or pelvic lymphadenectomy might be appropriate.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adult. Aged. Aorta. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Cystadenocarcinoma, Serous / secondary. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovariectomy. Pelvis. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112940.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH: Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res; 2008 Feb 1;68(3):759-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
  • Here we show that female mice heterozygous for a null Lkb1 allele spontaneously develop highly invasive endometrial adenocarcinomas.
  • This endometrial-specific deletion of the Lkb1 gene provoked highly invasive and sometimes metastatic endometrial adenocarcinomas closely resembling those observed in Lkb1 heterozygotes.
  • Although Lkb1 has been implicated in the establishment of cell polarity, and loss of polarity defines most endometrial cancers, Lkb1-driven endometrial cancers paradoxically exhibit (given their highly invasive phenotype) normal cell polarity and apical differentiation.
  • In human endometrial cancers, Lkb1 expression was inversely correlated with tumor grade and stage, arguing that Lkb1 inactivation or down-regulation also contributes to endometrial cancer progression in women.
  • This study shows that Lkb1 plays an important role in the malignant transformation of endometrium and that Lkb1 loss promotes a highly invasive phenotype.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Endometrial Neoplasms / genetics. Protein-Serine-Threonine Kinases / deficiency

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245476.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCRR NIH HHS / RR / K26RR024196
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


Advertisement
4. Ibáñez Pinto A, Fernández Salgado E, Castro Ortiz E, Baltar Arias R, Vázquez Vázquez S, Ledo Barro L, Vázquez San Luis J, Vázquez Astray E: [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy]. Gastroenterol Hepatol; 2007 Nov;30(9):530-4
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
  • [Transliterated title] Hemorragia digestiva de origen incierto por un adenocarcinoma endometrial metastásico. Respuesta al tratamiento hormonal.
  • BACKGROUND: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Gastrointestinal Hemorrhage / etiology. Medroxyprogesterone Acetate / therapeutic use. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / secondary. Retroperitoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980130.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Number-of-references] 19
  •  go-up   go-down


5. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev; 2005;(3):CD003915
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
  • BACKGROUND: Endometrial adenocarcinoma is a common gynaecological cancer, but a comparatively small proportion of patients present with or develop recurrent or advanced disease.
  • OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma.
  • Only one trial showed a significant survival benefit from the addition of paclitaxel to combination chemotherapy, but this was at the expense of increased toxicity.
  • There were no comparative trials of chemotherapy with endocrine therapy AUTHORS' CONCLUSIONS: The optimum cytotoxic drug regimen for advanced endometrial adenocarcinoma has still to be defined although our review suggests that it may contain paclitaxel or platinum.
  • These mainly North American and European trial populations represent a highly selected subgroup of the 10, 000 women dying annually from this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2005;(4):CD003915 [16235346.001]
  • (PMID = 16034916.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 109
  •  go-up   go-down


6. Orrrù S, Lay G, Dessì M, Murtas R, Deidda MA, Amichetti M: Brain metastases from endometrial carcinoma: report of three cases and review of the literature. Tumori; 2007 Jan-Feb;93(1):112-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from endometrial carcinoma: report of three cases and review of the literature.
  • AIMS AND BACKGROUND: Endometrial carcinoma is a rare cause of brain metastases, accounting for less than 1% of all metastatic lesions to the brain.
  • This report aims to review our experience in the treatment of patients with brain metastases from endometrial carcinoma in order to establish the characteristics of these patients and evaluate the results and efficacy of whole-brain radiation therapy as a palliative measure.
  • METHODS: Three cases of brain metastases from endometrial carcinoma treated with radiotherapy were identified in the files of the Division of Radiotherapy at the A.
  • CONCLUSIONS: The combination of surgery and postoperative whole-brain irradiation in selected patients with solitary brain metastases from endometrial carcinoma is an effective method of palliation.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455884.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Blazer DG 3rd, Ramirez PT, Wang H, Fleming JB: Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. JOP; 2008;9(1):56-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas.
  • Pancreatic resection for metastatic disease is rare but can produce durable palliation or even cure in carefully selected patients.
  • Herein, we report what to our knowledge is the first description of pancreatic resection of metastatic endometrial carcinoma.
  • CASE REPORT: We evaluated a patient who developed a mass in the distal pancreas as identified by screening computed tomography nearly three years after radical abdominal hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymph node dissection for an International Federation of Gynecology and Obstetrics stage IIIA, grade 2 endometrial cancer.
  • Findings on cytopathologic examination of tissue obtained by fine needle aspiration of the lesion were consistent with metastatic endometrial carcinoma.
  • CONCLUSION: Metastasis to the pancreas from endometrial cancer is uncommon; however, this possibility should be considered in patients with a new pancreatic lesion and a history of endometrial cancer as pancreatic resection of metastatic disease can benefit selected patients.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Endometrial Neoplasms / pathology. Pancreatectomy. Pancreatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182745.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J: Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev; 2005;(4):CD003915
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
  • BACKGROUND: Endometrial adenocarcinoma is a common gynaecological cancer, but a comparatively small proportion of patients present with or develop recurrent or advanced disease.
  • OBJECTIVES: To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma.
  • Only one trial showed a significant survival benefit from the addition of paclitaxel to combination chemotherapy, but this was at the expense of increased toxicity.
  • AUTHORS' CONCLUSIONS: The optimum cytotoxic drug regimen for advanced endometrial adenocarcinoma has still to be defined although our review suggests that it may contain paclitaxel or platinum.
  • These mainly North American and European trial populations represent a highly selected subgroup of the 10,000 women dying annually from this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2012;8:CD003915 [22895938.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(3):CD003915 [16034916.001]
  • (PMID = 16235346.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 109
  •  go-up   go-down


10. Castillo-Sang M, Slam K, Gociman B, Durham SJ, Booth R: Endometrial adenocarcinoma metastatic to the right ventricle: a case report and review of the literature. Cardiovasc Pathol; 2009 May-Jun;18(3):178-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma metastatic to the right ventricle: a case report and review of the literature.
  • BACKGROUND: Endometrial adenocarcinoma of any histologic type rarely metastasizes to the heart.
  • Her past medical history was significant for a resected Stage IC endometrial adenocarcinoma endometrioid type 15 months prior.
  • The tumor was found to be a poorly differentiated (Grade 3) endometrial adenocarcinoma invading over half the myometrium.
  • Subsequent endocardial biopsy showed a poorly differentiated, Grade 3, endometrial adenocarcinoma of endometrioid histologic type.
  • CONCLUSION: Management of metastatic adenocarcinoma to the heart is not well established due to the rarity of this lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402828.001).
  • [ISSN] 1879-1336
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


11. Kanjwal K, Colyer W Jr: Transthoracic echocardiography-guided biopsy of a metastatic endometrial adenocarcinoma in the right atrium: a review of diagnosis and treatment of cardiac masses. Am J Ther; 2010 Jul-Aug;17(4):e118-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic echocardiography-guided biopsy of a metastatic endometrial adenocarcinoma in the right atrium: a review of diagnosis and treatment of cardiac masses.
  • We report on a 64-year-old African-American female with a past medical history of an endometrial adenocarcinoma with metastasis to the right atrium.
  • To our knowledge, there have been only four case reports on endometrial carcinoma metastasizing to the right atrium.
  • Histopathologic evaluation of the specimens revealed an adenocarcinoma, consistent with the patient's history of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Echocardiography / methods. Endometrial Neoplasms / diagnosis. Heart Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20027104.001).
  • [ISSN] 1536-3686
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol; 2005 Nov;99(2):472-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
  • BACKGROUND: Conservative treatment with progestins is a reasonable treatment option for endometrial complex atypical hyperplasia and, in the experimental setting, for some women with grade 1 endometrial endometrioid adenocarcinoma.
  • The risk of progression to a high-stage endometrial cancer is quite low, with only two previously reported cases in the English literature.
  • CASE: A 40-year-old woman with endometrial complex atypical hyperplasia diagnosed by dilatation and curettage was managed conservatively with progestin therapy (initially, megesterol acetate; then, a combination oral contraceptive).
  • More than 2 years after her original diagnosis, she developed endometrial endometrioid adenocarcinoma, FIGO grade 2, with lymph node metastasis.
  • CONCLUSION: Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy.
  • There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage.
  • In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / drug therapy. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099019.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


13. Walrath JD, Lelli GJ Jr, Engelbert M, Kazim M: Metastatic endometrial carcinoma resulting in orbital apex compression. Ophthal Plast Reconstr Surg; 2007 May-Jun;23(3):250-1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic endometrial carcinoma resulting in orbital apex compression.
  • A 63-year-old woman presented subacutely with signs of orbital apex and cavernous sinus disease in the setting of widespread, untreated metastatic carcinoma of the uterus.
  • The underlying diagnosis was confirmed with repeat endometrial biopsy, revealing well-differentiated endometrial adenocarcinoma.
  • Given the supporting clinical evidence for metastatic disease and the radiologic characteristics of the lesion, the decision was made to not perform a confirming orbital biopsy.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Nerve Compression Syndromes / etiology. Optic Nerve Diseases / etiology. Orbital Neoplasms / secondary. Paranasal Sinus Diseases / etiology

  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519676.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Jewell E, Secord AA, Brotherton T, Berchuck A: Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer; 2006 May-Jun;16(3):1370-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of trastuzumab in the treatment of metastatic endometrial cancer.
  • Systemic therapy of metastatic endometrial cancer is relatively ineffective.
  • In this case, we present a 76-year-old woman with stage IIIA endometrial adenocarcinoma who was initially treated with surgery and pelvic radiation.
  • Immunostaining revealed that the primary endometrial cancer overexpressed HER-2/neu.
  • Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803532.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Uharcek P, Mlyncek M, Ravinger J: Endometrial adenocarcinoma presenting with an osseous metastasis. Gynecol Obstet Invest; 2006;61(4):200-2
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma presenting with an osseous metastasis.
  • BACKGROUND: Gynecologic cancers metastatic to bone are rare.
  • Endometrial carcinoma usually presents with vaginal bleeding.
  • Biopsy revealed primary endometrioid carcinoma metastatic to the calcaneus, talus and metatarsal bones.
  • CONCLUSION: Endometrial carcinoma can present as a metastatic lesion of bone.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Endometrial Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16479137.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


16. Goel R, Chen E, Welch S, Laurie S, Siu L, Jonker D, Srinivasan R, Wang L, Ivy P, Oza A, Princess Margaret Hospital Phase II Consortium: Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two prior chemotherapy regimens for metastatic disease were allowed.
  • RESULTS: Patient characteristics: male 11/female 10; median age 59 (range 28-84); performance status 0 /1/2: n=1/13/7; prior chemotherapy 21, prior radiotherapy 7, prior immunotherapy 1; tumour types: ovarian cancer 3, endometrial cancer 3, NSCLC 3, gastric/esophageal adenocarcinoma 3, miscellaneous 9.
  • RESPONSE: partial response 1 (ovarian cancer), stable 8 [minor response 4 (NSCLC 2, endometrial cancer 1, head and neck cancer 1)], progression 8, inevaluable 4.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Murakami F, Ogawa N, Yamazaki A, Sakurai S, Ishiya T, Katase K, Shimizu Y, Tanada S: Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between May 2007 to August 2008, 36 consecutive patients (pts) with cervical carcinoma, endometrial carcinoma and epithelial ovarian carcinoma were enrolled.
  • For pathological metastatic lymph nodes, the size of intranodal tumor deposits (maximum diameter of metastatic foci in each lymph node) were recorded.
  • The sensitivity, specificity and accuracy of preoperative PET-CT to detect LN metastasis were 24%, 99.9%, and 97.5%, respectively.
  • The sensitivity of squamous cell carcinoma (SCC) were 35.7%, that of adenocarcinoma were 8.1%.
  • CONCLUSIONS: The results of our study revealed 76% underdiagnosis (overlooking) in evaluation of preoperative PET-CT in LN metastasis.
  • Using PET-CT for detecting small LN metastasis in gynecologic carcinoma may be unreliable so far.
  • However we found that PLNs are comparatively easy to be detected than PANs, and SCC are comparatively easy to be detected than adenocarcinoma.
  • The improved usability and application of PET-CT for detecting LN metastasis in gynecologic carcinoma have to keep researching constructively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Nawaz I, Smith PR, Mamidwar M: Endobronchial metastases from endometrial carcinoma. J Bronchology Interv Pulmonol; 2009 Jul;16(3):219-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial metastases from endometrial carcinoma.
  • A 78-year-old woman status post hysterectomy and radiation therapy 3 years earlier for endometrial carcinoma presented with cough, dyspnea, and weight loss.
  • Endobronchial biopsy revealed metastatic adenocarcinoma with histology similar to the previously resected endometrial primary and immunohistochemical staining consistent with endometrial carcinoma.
  • To our knowledge, endobronchial metastases from endometrial carcinoma have been reported only once before.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23168560.001).
  • [ISSN] 1944-6586
  • [Journal-full-title] Journal of bronchology & interventional pulmonology
  • [ISO-abbreviation] J Bronchology Interv Pulmonol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kefeli M, Gonullu G, Can B, Malatyalioglu E, Kandemir B: Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature. Int J Gynecol Pathol; 2009 Jul;28(4):343-6
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of adenocarcinoma of the gall bladder to an endometrial polyp detected by endometrial curettage: case report and review of the literature.
  • SUMMARY: Polyps are the most common benign lesions in the endometrium.
  • Metastasis to the endometrial polyp from a distant primary tumor is rare.
  • Breast carcinoma is the most frequent extragenital cancer that metastasizes to the endometrial polyp.
  • We report the case of a 63-year-old with metastatic gall bladder adenocarcinoma involving endometrial polyps detected by endometrial curetting.
  • It was the first sign of her metastatic disease.
  • Gastrointestinal tumor metastasis to an endometrial polyp is a very rare event, but if a patient with a known primary extragenital tumor has abnormal vaginal bleeding, the possibility of metastasis should be included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / secondary. Gallbladder Neoplasms / pathology. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483630.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


20. Pectasides D, Pectasides E, Economopoulos T: Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev; 2007 Apr;33(2):177-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy in metastatic or recurrent endometrial cancer.
  • Endometrial cancer is one of the most common gynecologic malignancies.
  • In patients with advanced or recurrent endometrial cancer survival is greatly diminished.
  • Hormonal therapy and chemotherapy play a major role in the management of advanced or recurrent endometrial cancer.
  • The combination of cisplatin plus doxorubicin is the most commonly used regimen, but carboplatin plus paclitaxel represents an efficacious, low toxicity regimen in advanced or recurrent endometrial cancer.
  • At this time the focus of future research should be on the use of novel targeted agents, since it is unlikely that further significant advances could be made with chemotherapy and endocrine therapy. mTOR inhibitors represent a promising therapeutic strategy for endometrial cancer.
  • Anti-HER-2/neu targeted therapy might be a novel and attractive therapeutic option in patients with biologically aggressive variants (uterine serous papillary carcinoma, clear cell carcinoma) of endometrial cancer.
  • Research in better understanding the signal transduction pathways in endometrial carcinogenesis will allow the development of specific and selective molecularly targeted inhibitors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy


21. Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER: Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol; 2006 Oct;103(1):25-30
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma.
  • OBJECTIVES: The current study sought to determine if endometrial adenocarcinomas express human leukocyte antigen-G (HLA-G), an immune-regulatory protein, and if degree of expression correlates with the stage of carcinoma.
  • METHODS: Forty-four primary endometrial adenocarcinomas were tested using immunohistochemical staining with the 4H84 anti-HLA-G monoclonal antibody.
  • Metastatic implants were not included.
  • RESULTS: Immunohistochemical staining for HLA-G protein was seen in 55% (24/44) of primary site endometrial adenocarcinomas and localized to glandular but not stromal epithelium.
  • A significant correlation was seen with increasing HLA-G protein staining and increasing stage of endometrial cancer, P < 0.01.
  • HLA-G was found to be a fair discriminator as a test for metastatic disease with an area under the ROC curve of 0.75 for metastatic versus non-metastatic disease.
  • CONCLUSIONS: HLA-G protein is expressed in a significant number of endometrial adenocarcinomas, in which it is localized to the glandular epithelium.
  • HLA-G may serve as a clinical marker for the preoperative prediction of metastatic endometrial cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Endometrial Neoplasms / immunology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530254.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


22. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • Metastatic tumors within the cervix are uncommon if one excludes endometrial carcinoma, which involves the cervix by direct spread.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.


23. Akcaer M, Milman T, Finger PT: Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body. Ophthalmic Surg Lasers Imaging; 2008 May-Jun;39(3):246-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body.
  • A 60-year-old woman with endometrioid adenocarcinoma (stage FIGO II) presented with left eye pain.
  • Positron emission tomography and computed tomography fusion revealed multifocal metastatic disease.
  • A Finger iridectomy technique ciliary body tumor biopsy revealed metastatic endometrioid adenocarcinoma.
  • This is the first reported case of endometrioid adenocarcinoma of the uterus metastatic to the uveal tract.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / secondary. Ciliary Body. Endometrial Neoplasms / pathology. Uveal Neoplasms / diagnosis. Uveal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556953.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Olcha P, Cybulski M, Skomra D, Obrzut B, Ignatov A, Jóźwik M, Schneider-Stock R, Semczuk A: The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations. Int J Gynecol Cancer; 2010 Aug;20(6):993-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of p14ARF expression in primary and metastatic human endometrial carcinomas: correlation with clinicopathological features and TP53 pathway alterations.
  • OBJECTIVES: Alterations of p53 pathway (p14(ARF)/MDM2/p53) play a crucial role in the development and progression of various human neoplasms, including endometrial carcinoma (EC).
  • The aim of the current research was to examine the p14(ARF) expression pattern in primary ECs and corresponding metastatic lesions.
  • MATERIALS AND METHODS: We studied 47 primary ECs and corresponding metastatic lesions applying immunohistochemistry and investigated the relationship between p14(ARF) overexpression and clinicopathological variables of carcinoma as well as TP53 alterations.
  • RESULTS: Protein expression was predominantly nuclear, present in 32 (68%) of 47 primary cases and in 28 (60%) of 47 metastatic lesions.
  • There were seven p14(ARF)-positive primary tumors showing negative reactivity in the metastatic lesions.
  • A case of primary cervical adenocarcinoma metastasizing to the lymph nodes showed p14(ARF) expression both in the primary tumor and the corresponding metastases.
  • CONCLUSIONS: Altogether, the p14(ARF) protein is expressed in more than half of the primary ECs and metastatic lesions analyzed and is associated with the transtubal dissemination of the primary tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / secondary. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Tumor Suppressor Protein p14ARF / metabolism. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683407.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


25. Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J: Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril; 2007 Dec;88(6):1562-7
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma.
  • OBJECTIVE: To evaluate IVF characteristics and outcome of infertile women conservatively treated for well-differentiated endometrial adenocarcinoma.
  • PATIENT(S): Eight women referred to IVF treatment because of failure of other fertility treatments after conservative treatment of endometrial adenocarcinoma.
  • All women were selected carefully for conservative treatment at the Department of Gynecology Oncology of the Chaim Sheba Medical Center after a thorough metastatic workup.
  • MAIN OUTCOME MEASURE(S): Serum E(2) levels at hCG administration, endometrial thickness, number of oocytes retrieved, fertilization rate, pregnancy and delivery rate.
  • In four of them, endometrial adenocarcinoma was diagnosed during infertility workup or treatment.
  • CONCLUSION(S): In vitro fertilization treatment of infertile women conservatively treated for well-differentiated endometrial adenocarcinoma is highly successful and offers the opportunity to cryopreserve embryos for future use.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Infertility, Female / therapy. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412340.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


26. Rettenmaier NB, Epstein HD, Oi S, Robinson PA, Goldstein BH: Cerebral nocardia masquerading as metastatic CNS disease in an endometrial cancer patient. Eur J Gynaecol Oncol; 2009;30(1):90-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral nocardia masquerading as metastatic CNS disease in an endometrial cancer patient.
  • We present the case of a 61-year-old woman previously treated for endometrial carcinoma, who three years later developed metastatic pulmonary disease and received systemic chemotherapy.
  • After five months, she developed a large right posterior lobe lesion, suspicious for metastatic CNS disease.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Abscess / diagnosis. Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Nocardia Infections / diagnosis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


27. Roncati L, Barbolini G, Ghirardini G, Rivasi F: Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report. Int J Surg Pathol; 2010 Dec;18(6):561-3
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report.
  • This mass was noted on CT scan and considered metastatic in nature since following a bioptical diagnosis of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282291.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Altundag O, Dursun P, Ayhan A: Emerging drugs in endometrial cancers. Expert Opin Emerg Drugs; 2010 Dec;15(4):557-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs in endometrial cancers.
  • IMPORTANCE OF THE FIELD: Endometrial cancer remains the most common gynecologic malignancy.
  • The treatment of endometrial cancer is rapidly evolving.
  • AREAS COVERED IN THIS REVIEW: In this article, we aim to review current and future treatment options in the medical treatment of endometrial cancers.
  • WHAT THE READER WILL GAIN: The cornerstone of curative therapy for patients with endometrial cancer is surgical treatment.
  • Cytotoxic chemotherapy is the mainstay of therapy for metastatic and advanced endometrial cancer.
  • Recent advances in the understanding of the molecular biology of endometrial cancer have led to development of targeted therapies.
  • TAKE HOME MESSAGE: Clinical trials are planned to further explore how to best incorporate novel agents into the current treatment algorithm with the aim to improve outcome for women with endometrial adenocarcinomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Algorithms. Animals. Clinical Trials as Topic. Drug Design. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20828226.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Giordano G, Gnetti L, Melpignano M: Endometrial carcinoma metastatic to the vulva: a case report and review of the literature. Pathol Res Pract; 2005;201(11):751-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma metastatic to the vulva: a case report and review of the literature.
  • In this paper, we report a new case of metastatic endometrial carcinoma to the vulva and describe the clinical and pathological features.
  • Moreover, we discuss the criteria for the differential diagnosis of endometrial carcinoma metastatic to the vulva, the primary vulvar adenocarcinomas, and other metastatic adenocarcinomas.
  • The patient, previously diagnosed to have endometrial adenocarcinoma with squamous differentiation at III C stage (according to the FIGO system) and T2N1M0 stage (according to the TNM system), presented with a small plaque on the vulvar mucosa 8 months after endometrial primary carcinoma had been diagnosed.
  • The histological evaluation of excisional vulvar biopsy revealed a neoplasm with pathological features of endometrial carcinoma.
  • Thus, the final diagnosis was metastatic endometrial carcinoma to the vulva.
  • A total body computed tomography scan (CT) and an echotomography with contrast medium revealed a second metastatic lesion at the 8th segment of the liver.
  • No other metastatic lesions developed, nor was a reduction in the size of liver metastasis observed after 3 months of hormonic treatment with progesterone.
  • Fourteen months after the diagnosis of primary endometrial carcinoma, the patient died of disseminated metastatic lesions.
  • In conclusion, metastatic endometrial carcinoma to the vulva, although rare, might develop and could appear within a few months after the diagnosis of primary tumor.
  • Moreover, in the presence of metastatic endometrial carcinoma to the vulva, it is necessary to verify if other visceral metastases are present.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325518.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 17
  •  go-up   go-down


30. Barker LC, Brand IR, Crawford SM: Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin; 2009 May;25(5):1105-9
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
  • OBJECTIVE: To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment.
  • MAIN OUTCOME MEASURE: Resolution of endometrial thickening measured by transvaginal ultrasound at 3-month intervals; the response of metastases was assessed by standard oncological criteria.
  • During treatment with AIs, mean endometrial thickness in the eight patients with EH decreased progressively by 81.7% from 14.7 mm at the start of treatment to 2.7 mm following 36 months of treatment.
  • A greater original mean endometrial thickness of 17 mm was seen in the four patients with localised EA, this fell progressively by 67.1% to 5.6 mm following 36 months of treatment.
  • No responses were seen in four patients with metastatic disease.
  • CONCLUSION: Our results indicate that treatment of EH with anastrozole or letrozole can reduce endometrial thickness as seen ultrasonically, and that in some cases AI treatment can reduce endometrial thickness in patients with localised EA.
  • We found no evidence to indicate that AI treatment prevents disease progression in patients with metastatic EA.
  • [MeSH-major] Aromatase Inhibitors / pharmacology. Carcinoma / drug therapy. Endometrial Hyperplasia / drug therapy. Endometrial Neoplasms / drug therapy. Endometrium / drug effects. Nitriles / pharmacology. Triazoles / pharmacology

  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301987.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; 7LKK855W8I / letrozole
  •  go-up   go-down


31. Kaya A, Olmezoglu A, Eren CS, Bayol U, Altay T, Karapinar L, Ozturk H, Oztekin D, Guvenli Y, Karadogan I: Solitary bone metastasis in the tibia as a presenting sign of endometrial adenocarcinoma: a case report and the review of the literature. Clin Exp Metastasis; 2007;24(2):87-92
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary bone metastasis in the tibia as a presenting sign of endometrial adenocarcinoma: a case report and the review of the literature.
  • BACKGROUND: Metastasis to bone from endometrial adenocarcinoma is rare, when metastasises it usually locates in axial skeleton.
  • In the present study we report the 10th cases of bone metastasis in the literature which located at tibial diaphysis and originated from endometrial adenocarcinoma as a presenting feature of the primary disease.
  • Biopsy confirmed metastatic adenocarcinoma of the unknown origin.
  • Endometrial adenocarcinoma is detected after the end of disease-free one year with the symptom of vaginal bleeding.
  • DISCUSSION: Patients with endometrial adenocarcinoma presenting an isolated skeletal metastasis may exhibit an unusual group with a better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Endometrial Neoplasms / pathology. Tibia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364220.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. McCluggage WG, Young RH: Endometrial stromal sarcomas with true papillae and pseudopapillae. Int J Gynecol Pathol; 2008 Oct;27(4):555-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial stromal sarcomas with true papillae and pseudopapillae.
  • Most endometrial stromal sarcomas (ESSs) have a characteristic histologic appearance and the diagnosis is easily made based on the typical growth pattern, vascular pattern, and cell type.
  • In the third case, there was a true papillary component involving sex cord-like elements within an ESS and a prominent papillary architecture in the metastatic tumor which developed 7 years later resulted in initial misdiagnosis as a serous adenocarcinoma.
  • [MeSH-major] Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753964.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A: Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol; 2008 Sep 10;26(26):4319-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
  • PURPOSE: Epidermal growth factor receptor (EGFR) overexpression is common in endometrial cancers and may have a major role in tumor growth and progression.
  • PATIENTS AND METHODS: A multinomial design two-stage phase II study was performed to evaluate single-agent activity of erlotinib in women with advanced endometrial cancer with recurrent or metastatic disease who were chemotherapy naïve and had received up to one line of prior hormonal therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use


34. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Childs AJ, Burke JJ 2nd, Perry MY, Gallup DG: Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases. J Reprod Med; 2005 Mar;50(3):209-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases.
  • BACKGROUND: Endometrial carcinoma is the most common cancer of the female genital tract.
  • CASES: Two cases of uterine serous carcinoma were confined to an endometrial polyp without myometrial invasion and were widely metastatic.
  • Pathology showed metastatic disease originating in a small focus of serous adenocarcinoma at the tip of an endometrial polyp.
  • [MeSH-major] Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Polyps / pathology. Uterine Neoplasms / etiology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841935.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Tretheway D, Gebhardt JG, Dogra VS, Schiffhauer LM: Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature. Int J Gynecol Pathol; 2009 May;28(3):256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature.
  • We report a case of an oncocytic papillary adenocarcinoma of the endometrium in an 89-year-old female with vaginal bleeding.
  • Diagnostic workup included an endometrial biopsy which showed malignant, oncocytic cells in a predominantly papillary pattern.
  • Consultation with experts in Gynecologic and Genitourinary pathology returned a diagnosis of "adenocarcinoma compatible with metastatic renal cell carcinoma"--an intriguing possibility worthy of further exploration.
  • To our knowledge, there are no reports in the literature of metastatic oncocytic papillary renal cell carcinoma to the endometrium.
  • The clinical and pathologic features of oncocytic papillary endometrial lesions, including primary and metastatic processes, are reviewed.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620943.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


37. Mountzios G, Bamias A, Voulgaris Z, Rodolakis A, Vlahos G, Gourgoulis G, Papaiakovou EE, Giannopoulos A: Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model. Gynecol Oncol; 2008 Jan;108(1):130-5
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
  • OBJECTIVE: Taxane-based chemotherapy has been recently introduced as an effective therapeutic option in recurrent or metastatic endometrial carcinoma (RMEC).
  • Non-endometriod histology was associated with a shorter median survival compared to endometriod adenocarcinoma (14.46 vs. 17.57 months, p=0.093), but histology was not an independent prognostic factor (HR=1.43, 95% CI: 0.82-2.48, p=0.21).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988722.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Ikeda S, Yajima M, Hida K, Hattori M, Shimizu S, Umezaki I, Nishikawa T, Ohta H: Sister Joseph umbilical nodule coexisting with endometriosis from endometrial carcinoma. Arch Gynecol Obstet; 2006 Jan;273(4):250-2
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Joseph umbilical nodule coexisting with endometriosis from endometrial carcinoma.
  • A 58-year-old woman was diagnosed with endometrial carcinoma.
  • The nodule was identified as a metastasis from endometrial cancer with endometriosis.
  • The pelvic lymph nodes also showed metastatic lesion with endometriosis.
  • Our case showed that endometriosis coexisted with umbilical and pelvic lymph nodal metastatic lesions from endometrial cancer.
  • This fact suggests that the mode of metastasis to the umbilicus via lymph flow from endometrial cancer is the same as that for endometriosis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Endometriosis / complications. Umbilicus / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096837.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Jobo T, Sato R, Arai T, Tamura T, Watanabe J, Kuramoto H: Lymph node pathway in the spread of endometrial carcinoma. Eur J Gynaecol Oncol; 2005;26(2):167-9
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node pathway in the spread of endometrial carcinoma.
  • OBJECTIVE: To elucidate the sentinel nodes of endometrial carcinoma, the spread pathway was clarified.
  • The metastatic sites were most frequent in the obturator and internal iliac nodes.
  • CONCLUSION: The lymph node spread pathway in endometrial carcinoma consists of a major route via the obturator node or internal iliac node with or without parametrial involvement, and rarely a direct PAN pathway.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymphatic Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857023.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH: Overexpression of the alphavbeta6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol; 2008 Dec;16(6):543-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the alphavbeta6 integrin in endometrial cancer.
  • The alpha(v)beta(6) integrin (alphavbeta6) has been shown to be up-regulated in adenocarcinoma of the breast, colon, stomach, and ovary, generally reflecting a more aggressive phenotype.
  • Expression in endometrial cancer has not been reported.
  • We analyzed alphavbeta6 expression in the tissue from primary endometrial carcinomas (endometrioid type) using a mouse monoclonal antibody against human alphavbeta6, and correlated the findings with grade, stage, and nodal involvement.
  • Normal cycling endometrium was studied for comparison. alphavbeta6 was only weakly expressed in normal epithelium and infrequently expressed in precancers, but up-regulated in the majority of endometrial carcinomas, especially with high grade.
  • Overexpression of alphavbeta6 in endometrial carcinoma is common.
  • Expression is high in metastatic lesions.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698261.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / integrin beta6
  •  go-up   go-down


41. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol; 2008 Sep;199(3):e7-e10
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
  • Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician.
  • We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550023.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


42. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol; 2007 Mar;18(3):409-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
  • BACKGROUND: Cytotoxic chemotherapy has a limited place in the management of advanced or recurrent endometrial cancer.
  • While early-stage endometrial adenocarcinoma is a common gynaecological cancer with a favourable prognosis, advanced or recurrent disease presents a difficult management problem.
  • Data were extracted from trial reports or supplied by investigators.
  • Future developments are likely to exploit specific molecular characteristics of endometrial cancers, including their hormone dependence, growth factor target overexpression and PTEN loss.
  • While no one drug or regimen offers a clear benefit for women with advanced endometrial cancer, platinum drugs, anthracyclines and paclitaxel seem the most promising agents.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150999.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861323
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 57
  •  go-up   go-down


43. Michener CM, Peterson G, Kulp B, Webster KD, Markman M: Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol; 2005 Sep;131(9):581-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
  • PURPOSE: To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer.
  • METHODS: Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease.
  • CONCLUSIONS: The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma.
  • The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15959825.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


44. Pan Z, Repertinger S, Leonard R, Bewtra C, Gatalica Z, Sharma P: Cervical and endometrial metastases of appendiceal goblet cell carcinoid. Arch Pathol Lab Med; 2010 May;134(5):776-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical and endometrial metastases of appendiceal goblet cell carcinoid.
  • Appendiceal goblet cell carcinoid (GCC) is a rare tumor with histologic features of both adenocarcinoma and neuroendocrine tumor (carcinoid).
  • We report 2 cases of appendiceal GCC, one with uterine cervical involvement and the other with endometrial involvement as the initial presentations.
  • The second patient presented with abnormal uterine bleeding, and endometrial curettage showed an adenocarcinoma with signet ring cell features.
  • Metastatic appendiceal GCC to uterine cervix and endometrium can potentially be misinterpreted as primary cervical or endometrial signet ring cell carcinoma.
  • Therefore, for any uterine cervical/endometrial signet ring cell carcinoma, a metastatic appendiceal GCC should be considered in the differential diagnosis, especially after excluding other primary sites.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Carcinoid Tumor / secondary. Endometrial Neoplasms / secondary. Uterine Cervical Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441511.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Kinugasa Y, Morishige K, Kamiura S, Tsukamoto Y, Saji F: Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma. Jpn J Clin Oncol; 2006 Feb;36(2):113-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma.
  • The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy.
  • The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion.
  • To the best of our knowledge, this is the first reported case of hypercalcemia due to PTHrP secretion in uterine endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / pathology. Hypercalcemia / etiology. Parathyroid Hormone-Related Protein / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418186.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


46. Labi FL, Evangelista S, Di Miscia A, Stentella P: FIGO Stage I endometrial carcinoma: evaluation of lung metastases and follow-up. Eur J Gynaecol Oncol; 2008;29(1):65-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FIGO Stage I endometrial carcinoma: evaluation of lung metastases and follow-up.
  • PURPOSE: The aim of our study was to evaluate the incidence of lung metastases in the follow-up of women submitted to surgery for endometrial carcinoma, in particular for FIGO Stage I which is the lowest risk stage for this metastatic site.
  • METHODS: The study was conducted on 210 patients affected by FIGO Stage I endometrial cancer in the years 1990 to 2005 distributed as follows: 35 patients with Stage IA (limited to the endometrium), 150 patients with Stage IB (invasion up to and including half the myometrial thickness), 25 patients with Stage IC (invasion greater than half the myometrial thickness).
  • CONCLUSION: We are still following the cases and evaluating the biological behavior of this specific endometrial carcinoma and its reaction to further therapies.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386467.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


47. van der Horst C, Evans AJ: Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature. Int J Gynecol Cancer; 2008 May-Jun;18(3):549-53
MedlinePlus Health Information. consumer health - Peritoneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature.
  • Squamous differentiation in endometrial adenocarcinoma is common.
  • Keratin granulomas accompanied by viable adenocarcinoma cells are regarded as conventional metastatic foci.
  • However, the significance of keratin granulomas without accompanying viable adenocarcinoma cells is difficult to ascertain.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granuloma / pathology. Keratins / metabolism. Peritoneal Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645505.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


48. Katsumata N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, Aoki D, Susumu N, Kuramoto H, Jobo T, Ueki K, Ueki M, Kohno I, Fujiwara K, Sohda Y, Eguchi F: Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer; 2005 Oct 31;93(9):999-1004
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
  • The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma.
  • Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status </=2 entered the study.
  • Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Phytogenic / therapeutic use. Endometrial Neoplasms / drug therapy. Salvage Therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / secondary. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Female. Humans. Japan. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1991 Jun;9(6):1071-88 [2033421.001]
  • [Cites] Am J Clin Oncol. 1991 Feb;14(1):36-7 [1987736.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):52-7 [10873410.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2360-4 [11981008.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):78-85 [12504662.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):14-8 [14758127.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Gynecol Oncol. 1980 Aug;10(1):51-4 [7190531.001]
  • [Cites] Cancer Treat Rep. 1982 Aug;66(8):1669-71 [7105059.001]
  • [Cites] Cancer Treat Rep. 1983 Jul-Aug;67(7-8):737-8 [6871892.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1453-5 [8111713.001]
  • [Cites] Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8 [7670132.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):101-4 [8898177.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):610-5 [15721401.001]
  • [Cites] Am J Clin Oncol. 1984 Jun;7(3):253-6 [6539565.001]
  • [Cites] Am J Clin Oncol. 1986 Feb;9(1):15-7 [3953488.001]
  • [Cites] Am J Clin Oncol. 1986 Feb;9(1):21-3 [3754086.001]
  • [Cites] Am J Clin Oncol. 1988 Dec;11(6):612-3 [3055931.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):39-41 [2407103.001]
  • [Cites] Am J Clin Oncol. 1993 Dec;16(6):492-3 [8256763.001]
  • (PMID = 16234823.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Other-IDs] NLM/ PMC2361676
  •  go-up   go-down


49. Zepiridis L, Zafrakas M, Theodoridis TD, Kaplanis K, Dinas KK, Bontis JN: A unique case of palatinate tonsil metastasis from endometrial cancer. Eur J Gynaecol Oncol; 2009;30(2):229-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of palatinate tonsil metastasis from endometrial cancer.
  • A case of a 55-year-old woman presenting with a palatinate tonsil tumour two and half years after primary diagnosis of endometrioid endometrial adenocarcinoma (FIGO Stage IB, G2) and six months after local disease recurrence is presented.
  • The tonsillar malignancy was poorly differentiated and tumour cells were immunohistochemically positive to LMW keratin and EMA, and negative to HMW keratin and LCA, strongly suggesting a possible endometrial origin of the tumour.
  • Metastatic disease was treated with systemic chemotherapy, but the patient soon succumbed due to rapid disease progression.
  • In conclusion, a unique case of a palatinate tonsil tumour as the first metastatic site in an endometrial cancer patient is reported.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Tonsillar Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480265.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


50. Yamada T, Mori H, Kanemura M, Ohmichi M, Shibayama Y: Endometrial carcinoma with choriocarcinomatous differentiation: a case report and review of the literature. Gynecol Oncol; 2009 May;113(2):291-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma with choriocarcinomatous differentiation: a case report and review of the literature.
  • CASE: We present a case of a 58-year-old woman with endometrial carcinoma with choriocarcinomatous differentiation.
  • She received surgery and chemotherapy for endometrial adenocarcinoma.
  • However, a metastatic tumor of choriocarcinomatous element appeared at the vaginal cuff 9 months after surgery.
  • CONCLUSION: Treatment and follow-up must be performed not only for the adenocarcinoma element but also for the choriocarcinoma element in patients presenting with endometrial carcinoma with choriocarcinomatous differentiation.
  • [MeSH-major] Choriocarcinoma / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232701.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • AIM: To compare the survival and prognostic factors of patients with dual primary ovarian and endometrial cancers (primary group), and endometrial cancers metastatic to the ovaries (metastatic group).
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • Twenty-five were classified into the metastatic group.
  • RESULTS: The mean age of the primary group was significantly younger than that of the metastatic group (45.2 years vs 51.2 years; P < 0.01).
  • The cumulative 10-year survival of the primary group was significantly better than that of the metastatic group (90.9%vs 46.6%; P < 0.05).
  • Univariate analyses showed that older age (P < 0.05) and the presence of lymphovascular space invasion (LVSI; P < 0.004) of the tumor of the uterus were significantly associated with a poor prognosis in the metastatic group.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Cohn DE, Resnick KE, Ramirez NC, Morrison CD: Advanced endometrial cancer with serous metastasis in a 17-year-old. Gynecol Oncol; 2006 May;101(2):356-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced endometrial cancer with serous metastasis in a 17-year-old.
  • BACKGROUND: Endometrial cancers with a component of serous histology generally occur in postmenopausal women and can present with advanced disease even in the absence of a deeply myoinvasive primary malignancy.
  • We present a case of stage IIIC endometrial cancer with serous histology in a 17-year-old.
  • CASE: A 17-year-old presented with menorrhagia requiring blood transfusion and a transvaginal ultrasound demonstrated a 31 mm endometrial stripe within a bulky uterus.
  • Endometrial curettage revealed a grade 2 endometrioid adenocarcinoma.
  • The patient desired definitive surgical management for her disease; a stage IIIC endometrial cancer with focal low-grade serous carcinoma among a grade 2 endometrioid carcinoma was noted to be superficially myoinvasive.
  • Multiple pelvic lymph nodes had evidence of metastatic serous adenocarcinoma.
  • CONCLUSION: Advanced endometrial cancer with metastasis of serous carcinoma to the retroperitoneal lymph nodes can occur, albeit extraordinarily rarely, in very young women.
  • This information is critically important when counseling a woman regarding conservative management of endometrial adenocarcinoma with the interest of preservation of her fertility.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499956.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Dordević M, Mitrović S, Jovanović B, Dordević G: [Ovarian metastasis in patient with endometrial carcinoma or synchronous tumors--presentation of a case]. Med Pregl; 2010 Jul-Aug;63(7-8):570-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian metastasis in patient with endometrial carcinoma or synchronous tumors--presentation of a case].
  • Metastatic tumors originate by disseminating malignant cells from other organs.
  • Joined endometrial and ovarian carcinomas are found in 5% of cases.
  • PRESENTATION OF A CASE: In this research, we present the case of an obese woman, 37 years old, who had associated endometrial tumors of uterus and ovary, without malign cells in peritoneal dilution, positive estrogen. negative progestine and focal expression of p53 receptors present in about 10-15% tumor cells.
  • The differentiation of primary independent synchronous and metastatic tumors is important not only for the prognosis, but also for the choice of the therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21446151.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


54. Pellerin GP, Finan MA: Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol; 2005 Nov;193(5):1640-4
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis.
  • OBJECTIVE: The purpose of this study was to evaluate the experience with endometrial carcinoma in women < or =45 years of age at Ochsner Clinic Foundation, New Orleans, La.
  • STUDY DESIGN: We evaluated the clinical history, treatment, and follow-up of 38 women < or =45 years of age diagnosed with endometrial cancer.
  • RESULTS: Thirty-eight patients received primary treatment for endometrial cancer: stage I, 32 (84.2%); stage II, 1 (2.6%); stage III, 4 (10.5%); stage IV, 1 (2.6%).
  • At end of study period 32 women (84.2%) were alive with no evidence of disease, 5 had died of recurrent disease, and 1 died of metastatic breast cancer.
  • [MeSH-major] Adenocarcinoma. Endometrial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16260203.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Bassarak N, Blankenstein T, Brüning A, Dian D, Bergauer F, Friese K, Mylonas I: Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer; 2010;10:224

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
  • BACKGROUND: During surgery for endometrial cancer, a pelvic lymphadenectomy with or without para-aortic lymphadenectomy is performed at least in patients with risk factors (stage I, grading 2 and/or histological subtypes with higher risk of lymphatic spread), and is hence recommended by the International Federation of Obstetrics and Gynecology (FIGO).
  • Although lymph node metastases are important prognostic parameters, it has been contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial cancer, especially in endometrioid adenocarcinoma.
  • Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma.
  • METHODS: The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of endometrial adenocarcinoma.
  • RESULTS: Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15 (7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV.
  • Only 11 (5.1%) patients showed metastatic disease in the lymph nodes.
  • CONCLUSIONS: The performance of an operative lymphadenectomy resulted in better survival of patients with endometrioid adenocarcinoma.
  • Therefore, even in endometrioid adenocarcinoma, a pelvic and/or para-aortic lymphadenectomy should be performed.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):139-44 [11161851.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1304-14 [19231155.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):518-25 [14675670.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):2073-8 [15274403.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Am J Obstet Gynecol. 1997 Apr;176(4):777-88; discussion 788-9 [9125601.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3668-75 [15738538.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):92-7 [16406063.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):150-6 [17197012.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2434-44 [17911007.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6 [18395039.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1361-9 [18951214.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):125-36 [19070889.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2003 Apr;43(2):104-10 [12649583.001]
  • (PMID = 20492712.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2891635
  •  go-up   go-down


56. Rathi V, Hyde S, Newman M: Well-differentiated papillary mesothelioma in association with endometrial carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):793-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary mesothelioma in association with endometrial carcinoma: a case report.
  • We present a rare case of WDPM in association with high-grade endometrial carcinoma.
  • To our knowledge, there are only two previously reported cases in the English literature of WDPM in association with endometrial carcinoma.
  • CASE: A 62-year-old woman underwent pelvic surgery for a high-grade endometrial adenocarcinoma.
  • At laparotomy an extensive peritoneal nodular fibrotic reaction was present, raising the clinical possibility of metastatic disease; however, intraoperative frozen section reported this as a mesothelial reaction.
  • Cytologic examination of peritoneal washings revealed cohesive clusters of reactive-appearing mesothelial cells, some with papillary morphology, and no evidence of adenocarcinoma.
  • The peritoneal biopsies showed no metastatic carcinoma.
  • The endometrial tumor was an endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Papillary / complications. Carcinoma, Papillary / pathology. Cell Differentiation. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Mesothelioma / complications. Mesothelioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053542.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Lin CK, Yu MH, Chu TW, Lai HC: Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium. Taiwan J Obstet Gynecol; 2006 Dec;45(4):336-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • Patients with synchronous cervical and endometrial cancers are even rarer.
  • We describe a case of cervical squamous cell carcinoma and endometrial endometrioid adenocarcinoma occurring simultaneously in a 47-year-old woman presenting with massive menstrual bleeding.
  • Magnetic resonance imaging revealed a mass over the cervical region and endometrial lesions in the uterine cavity.
  • Surgical exploration disclosed a cervical tumor and erosion of the endometrium.
  • The pathologic findings were compatible with synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • It is practical to pay more attention to the differential diagnosis of primary and metastatic tumors.
  • The second primary cancer that occurs in an individual with endometrial cancer may offer an opportunity for early detection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Female. Humans. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175494.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


58. Dvalishvili I, Charkviani L, Charkviani T, Turashvili G, Burkadze G: Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma. Georgian Med News; 2005 Sep;(126):27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical prognostic factors and expression of cathepsin D in endometrioid adenocarcinoma.
  • The aim of our study was to evaluate the association between the expression of cathepsin D and clinical prognostic data in endometrioid adenocarcinoma of different histological grade.
  • We studied 104 postmenopausal women with diagnosis of endometrioid adenocarcinoma.
  • 4 mm sections were stained by hematoxylin and eosin, von Gieson, and histological type of cancer, metastatic lesion of lymph nodes and depth of myometrial invasion were evaluated.
  • Our results suggest that the expression of cathepsin D is associated with the higher histological grade of endometrioid adenocarcinoma, depth of myometrial invasion, lymph node positivity, coexistence of obesity and vaginal bleeding.
  • It seems that local invasion and metastatic spread of tumor should be preceeded by the expression of cathepsin D in stromal cells which can be assessed in grade 1 and 2 endometrioid adenocarcinomas.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cathepsin D / metabolism. Endometrial Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234588.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


59. Delpech Y, Cortez A, Coutant C, Callard P, Uzan S, Darai E, Barranger E: The sentinel node concept in endometrial cancer: histopathologic validation by serial section and immunohistochemistry. Ann Oncol; 2007 Nov;18(11):1799-803
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sentinel node concept in endometrial cancer: histopathologic validation by serial section and immunohistochemistry.
  • If the SN is not metastatic, then all other nodes should also be disease-free.
  • PATIENTS AND METHODS: Twenty-three patients (median age 69 years) with early endometrial cancer underwent a laparoscopic SN procedure based on a combined detection method, followed by complete laparoscopic pelvic lymphadenectomy.
  • Ten SNs (21.3%) from five patients (26.3%) were found to be metastatic at the final histologic assessment.
  • In 14 patients, no metastatic SN involvement was detected by H&E and IHC staining.
  • In these 14 patients, 120 non-SNs were examined by serial sectioning and IHC, and none were found to be metastatic.
  • CONCLUSION: The SN procedure appears to reliably predict the metastatic status of the regional lymphatic basin in patients with early endometrial cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709801.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


60. Albareda J, Herrera M, Lopez Salva A, Garcia Donas J, Gonzalez R: Sacral metastasis in a patient with endometrial cancer: case report and review of the literature. Gynecol Oncol; 2008 Dec;111(3):583-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacral metastasis in a patient with endometrial cancer: case report and review of the literature.
  • BACKGROUND: Bone involvement in endometrial cancer has been described in less than 15% of the patients with metastatic disease.
  • CASE: We present a case of a 62-year-old woman who underwent surgery for endometrial adenocarcinoma in December 2002 (FIGO stage IB grade 1).
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Bone Neoplasms / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Sacrum / pathology. Sacrum / surgery

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501410.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ferrandina G, Zannoni GF, Gallotta V, Foti E, Mancuso S, Scambia G: Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report. Gynecol Oncol; 2005 Oct;99(1):215-7
Hazardous Substances Data Bank. DYDROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of conservatively treated endometrial carcinoma after full term pregnancy: a case report.
  • INTRODUCTION: We describe a case of conservatively treated endometrial endometrioid (EE) adenocarcinoma which showed an aggressive clinical outcome after pregnancy.
  • CASE: A 30-year-old woman with a well differentiated EE adenocarcinoma decided to attempt a conservative approach and underwent progestin treatment with subsequent negative ultrasound and hysteroscopic controls.
  • Eight 8 months after delivery, an exploratory laparotomy documented disseminated poorly differentiated EE adenocarcinoma.
  • Staging work up revealed diffuse metastatic disease.
  • CONCLUSION: Conservative medical management of endometrial cancer in young women willing to preserve their reproductive potential, carries on potential risks.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2006 May;101(2):373-4; author reply 374-5 [16494931.001]
  • (PMID = 15979130.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 90I02KLE8K / Dydrogesterone
  •  go-up   go-down


62. Bidziński M, Dańska-Bidzińska A, Derlatka P, Sobiczewski P, Gmyrek L, Jońska-Gmyrek J, Panek G: [Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer]. Ginekol Pol; 2007 Jun;78(6):471-5
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer].
  • INTRODUCTION: The risk of endometrial cancer recurrence is estimated to be about 20%.
  • MATERIAL AND METHODS: Between the year 2001 and 2003, 203 from 243 patients with endometrial cancer underwent surgery.
  • Recognizing 2 or more metastatic lymph nodes significantly increased the risk of recurrences.
  • CONCLUSION: In patients with endometrial cancer the risk of recurrences increases when lymph node metastases are recognized.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Women's Health
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adult. Cystadenocarcinoma, Papillary / secondary. Cystadenocarcinoma, Papillary / surgery. Female. Genital Neoplasms, Female / secondary. Genital Neoplasms, Female / surgery. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Poland. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899704.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


63. Numnum TM, Leath CA 3rd, Straughn MJ Jr: Synchronous primary endometrial and ovarian carcinoma in a patient with marantic endocarditis. Obstet Gynecol; 2006 Sep;108(3 Pt 2):748-50
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary endometrial and ovarian carcinoma in a patient with marantic endocarditis.
  • A metastatic work-up revealed a complex pelvic mass and elevated CA 125.
  • The patient underwent an exploratory laparotomy and was subsequently found to have synchronous primary endometrial and ovarian carcinoma.
  • [MeSH-major] Endocarditis / complications. Endometrial Neoplasms / complications. Neoplasms, Multiple Primary / complications. Ovarian Neoplasms / complications
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Antineoplastic Agents / therapeutic use. Aortic Valve. CA-125 Antigen / blood. Carcinoma, Endometrioid / complications. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / therapy. Chest Pain. Combined Modality Therapy. Fallopian Tubes / surgery. Fatigue. Female. Heart Valve Diseases / surgery. Heart Valve Prosthesis. Humans. Hysterectomy. Omentum / surgery. Ovariectomy. Radiotherapy

  • Genetic Alliance. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Endocarditis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018489.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  •  go-up   go-down


64. Tsoi D, Buck M, Hammond I, White J: Gastric adenocarcinoma presenting as uterine metastasis--a case report. Gynecol Oncol; 2005 Jun;97(3):932-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma presenting as uterine metastasis--a case report.
  • CASE: We report a 75-year-old woman who underwent hysterectomy for a FIGO Grade I endometrial carcinoma and was found to have evidence of a second malignant process involving the myometrium.
  • Random biopsies, however, confirmed a diagnosis of primary gastric adenocarcinoma.
  • Malignant cells present deep in the lymphovascular spaces have morphological features different from the primary endometrial carcinoma.
  • The microscopic appearances of these cells are similar to that of the gastric biopsy, supporting the diagnosis of metastatic gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Stomach Neoplasms / diagnosis. Uterine Neoplasms / diagnosis. Uterine Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943994.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, Gold MA, McMeekin DS, Modesitt S, Cooper AL, Powell MA, Mutch DG, Nag S, Alvarez RD, Cohn DE: Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):886-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.
  • The objective of this study was to evaluate the treatment outcomes and risk factors of women with surgical stage I endometrial adenocarcinoma who were initially treated with surgery alone and subsequently developed isolated vaginal recurrences.
  • Patients with surgical stage I endometrial adenocarcinoma diagnosed from 1975 to 2002 were identified from tumor registry databases at seven institutions.
  • Metastatic disease in the chest and abdomen was excluded by radiologic studies.
  • Sixty-nine women with surgical stage I endometrial cancer with isolated vaginal recurrences were identified.
  • The majority of isolated vaginal recurrences in women with surgical stage I endometrial cancer can be successfully salvaged with radiation therapy, further questioning the role of adjuvant therapy for patients with uterine-confined endometrial cancer at the time of initial diagnosis.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309665.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


66. Powell JL, Cunill ES, Gajewski WH, Novotny DB: Sarcoidosis mimicking recurrent endometrial cancer. Gynecol Oncol; 2005 Dec;99(3):770-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis mimicking recurrent endometrial cancer.
  • In patients with recurrent gynecologic cancer, liver and intrathoracic lesions should undergo a biopsy to rule in metastatic malignancy, as clinical findings and CAT scan results may represent other disease processes.
  • CASE: A 67 year old woman had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic lymphadenectomy, and peritoneal cytology in 2001 for Stage I B grade 1 adenocarcinoma of the endometrium.
  • A CT scan of lungs, abdomen, and pelvis revealed extensive mediastinal adenopathy and multiple space occupying hepatic lesions worrisome for metastatic disease.
  • CONCLUSION: Sarcoid lesions may mimic metastatic disease in patients with malignancy, potentially leading to delayed and/or inappropriate therapy.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Sarcoidosis / diagnosis

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168469.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. McCluggage WG, Wilkinson N: Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology; 2005 Sep;47(3):231-47
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.
  • The ovary is a common site of metastatic tumour.
  • In this review metastatic colorectal, appendiceal, gastric, breast, pancreatic and biliary tract, hepatocellular, renal, transitional and cervical carcinomas and metastatic malignant melanoma involving the ovary are discussed, as is the issue of synchronous ovarian and endometrial carcinomas.
  • Peritoneal tumours, including primary peritoneal carcinoma, mesothelioma and intra-abdominal desmoplastic small round cell tumour, involving the ovary are also discussed, together with a variety of other rare, metastatic ovarian neoplasms.
  • Many metastatic adenocarcinomas involving the ovary, especially those exhibiting mucinous differentiation, closely mimic primary ovarian adenocarcinomas with morphologically bland areas simulating benign and borderline cystadenoma.
  • In recent years immunohistochemistry, especially but not exclusively differential cytokeratin (CK7 and CK20) staining, has been widely used as an aid to distinguish between a primary and secondary ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115224.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  • [Number-of-references] 114
  •  go-up   go-down


68. Maghraby HK, Elsarha AI, Saad RS: Peritumoral lymphatic vessel density as a prognostic parameter in endometrial carcinoma: an immunohistochemical study. Indian J Pathol Microbiol; 2010 Jul-Sep;53(3):465-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral lymphatic vessel density as a prognostic parameter in endometrial carcinoma: an immunohistochemical study.
  • CONTEXT: Lymphatic invasion and nodal metastasis play a major role in the spread and prognosis of endometrial adenocarcinoma (EC).
  • AIMS: In this study, we investigate tumor lymph-angiogenesis, detected by D2-40, as a predictive marker for the risk of lymph node (LN) metastasis and its relation to other prognostic parameters in EC.
  • MATERIALS AND METHODS: Fifty-five cases of EC treated with total hysterectomy and pelvic LN dissection were reviewed.
  • Peritumoral D2-40 lymphovascular counts correlated significantly with FIGO grade (P < 0.001), lymphovascular invasion (P = 0.001) and LN metastases (P = 0.005).
  • Intratumoral lymphovascular invasion detected by D2-40 showed significant correlation with LN metastases (P < 0.01).
  • CONCLUSIONS: Our study shows that assessing LVD with D2-40 in the endometrial carcinoma might be a valuable parameter for predicting patients having an increased risk of developing of metastatic disease.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Lymphatic Vessels / pathology. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20699504.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / monoclonal antibody D2-40
  •  go-up   go-down


69. Young RH: From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol; 2007 May;14(3):149-77
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
  • This is the second of a two-part consideration of metastatic tumors to the ovary.
  • Coverage of intestinal adenocarcinoma emphasizes the landmark 1987 paper of RH Lash and WR Hart.
  • The section on pancreatic neoplasms reemphasizes the problems caused by metastatic ductal carcinoma, considered primarily in Part I, and discusses less common issues such as spread of neuroendocrine and acinar cell carcinomas.
  • The section on appendiceal neoplasms highlights ovarian spread of diverse tumors ranging from typical intestinal-type adenocarcinoma to signet-ring cell carcinomas with various patterns which in the ovary may prompt diagnoses such as a goblet cell (mucinous) carcinoid tumor, but whose ovarian features place them in the category of a Krukenberg tumor.
  • The section on breast cancer emphasizes that, although usually a manifestation of late stage disease and often not bulky in the ovaries, metastatic breast cancer may form large masses which can represent the clinical presentation.
  • The section on lung tumors largely reflects information in a recent paper that small cell carcinoma and adenocarcinoma are the lung cancers that spread to the ovary most commonly.
  • The extremely broad differential diagnosis posed by metastatic malignant melanoma ranging from that of an oxyphilic tumor, to a small cell tumor, to a follicle-forming neoplasm, is then considered.
  • The sections on renal cell carcinoma and other urinary tract neoplasms emphasize the differential diagnosis of metastatic clear cell carcinoma and primary clear cell carcinoma, an issue usually resolvable by an awareness of the various features of the ovarian variant, rarely or never seen in the renal variant.
  • The section on metastatic sarcomas discusses endometrial stromal sarcomas, gastrointestinal stromal neoplasms, and miscellaneous other sarcomas.
  • The endometrial stromal tumors are problematic largely because the history of a primary tumor may be remote, in the ovaries the typical growth and vascular pattern of endometrial stromal neoplasms is not always conspicuous, and some endometrial stromal sarcomas in the ovary show sex cordlike patterns of growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452813.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


70. Ali TZ, Zakowski MF, Yung RC, Burroughs FH, Ali SZ: Exfoliative sputum cytology of cancers metastatic to the lung. Diagn Cytopathol; 2005 Sep;33(3):147-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exfoliative sputum cytology of cancers metastatic to the lung.
  • Thirty-five cases of secondary/metastatic tumors involving the lung and diagnosed on sputum were retrospectively reviewed from our cytopathology files for a period of 22 yr (1980-2001).
  • Cytological diagnoses included colonic adenocarcinoma (7 cases); non-Hodgkin's lymphoma (NHL; 5 cases); malignant melanoma (MM; 5 cases); breast carcinoma (5 cases); Hodgkin's lymphoma (HL; 3 cases); pancreatic adenocarcinoma (2 cases); prostatic adenocarcinoma (2 cases); and 1 case each of urothelial carcinoma, endometrial carcinoma, renal cell carcinoma, hepatic small-cell carcinoma, squamous-cell carcinoma (cervix), and leiomyosarcoma (LMS).
  • In non-lymphoid tumors (27 cases), isolated single malignant cells were seen in 7 (26%) cases (all cases of MM and prostatic adenocarcinoma), whereas 20 (74%) cases displayed fragments with intact tumor architecture.
  • Exfoliation of cancer cells in sputum from secondary tumors in the lung is a rare phenomenon in current-day practice, with metastatic colonic adenocarcinoma seen most commonly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078247.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, Sato Y, Aoyama H, Hayashi T, Kushima R: Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol; 2008 May;39(5):666-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
  • Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast have close histologic similarities.
  • We examined 23 serous papillary adenocarcinomas (16 ovarian, 5 endometrial, and 2 peritoneal) and 37 invasive micropapillary carcinomas of the breast (12 pure and 25 mixed types) on immunohistochemical expression of Wilm's tumor antigen-1 (WT1), CA125, and gross cystic disease fluid protein-15 (GCDFP-15), which have been reported to be useful in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
  • We consider CA125 to be not always useful in the differential diagnosis of serous papillary adenocarcinoma and invasive micropapillary carcinoma.
  • Although the positive rate of WT1 was significantly higher in serous papillary adenocarcinoma than in invasive micropapillary carcinoma, WT1 expression in endometrial serous papillary adenocarcinoma was infrequent (20%).
  • WT1 and GCDFP-15 could be useful markers for the differential diagnosis of ovarian and peritoneal serous papillary adenocarcinoma versus breast invasive micropapillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. CA-125 Antigen / analysis. Carrier Proteins / analysis. Endometrial Neoplasms / diagnosis. Genital Neoplasms, Female / diagnosis. Glycoproteins / analysis. Ovarian Neoplasms / diagnosis. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339419.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / WT1 Proteins
  •  go-up   go-down


72. Parini CL, Mathis D, Leath CA 3rd: Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging. Int J Gynecol Cancer; 2007 May-Jun;17(3):731-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging.
  • The patient reported a history of intermittent postmenopausal bleeding and an endometrial biopsy documented uterine carcinosarcoma.
  • Postoperative pathologic review and immunohistochemical staining with thyroid transcription factor-1 revealed metastatic adenocarcinoma consistent with her lung primary in her uterus and adnexa.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504386.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Baron M, Hamou L, Laberge S, Callonnec F, Tielmans A, Dessogne P: Metastatic spread of gynaecological neoplasms to the adrenal gland: case reports with a review of the literature. Eur J Gynaecol Oncol; 2008;29(5):523-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic spread of gynaecological neoplasms to the adrenal gland: case reports with a review of the literature.
  • Metastatic involvement of the adrenal glands due to gynaecological neoplasms is a relatively rare condition.
  • The aim of our study was to present four cases of metastases to the adrenal gland due to endometrial adenocarcinoma, ovarian and cervical cancer.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051827.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


74. Puppa G, Shozu M, Perin T, Nomura K, Gloghini A, Campagnutta E, Canzonieri V: Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report. BMC Cancer; 2007;7:103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small primary adenocarcinoma in adenomyosis with nodal metastasis: a case report.
  • A few of these glands were transformed into a moderately differentiated adenocarcinoma.
  • The endometrium was completely examined and tumor free.
  • The carcinoma was, therefore, considered to be an endometrioid adenocarcinoma arising from adenomyosis.
  • Four months later, an ultrasound scan revealed enlarged pelvic lymph nodes: a cytological diagnosis of metastatic adenocarcinoma was made.
  • Immunohistochemical studies showed an enhanced positivity of the tumor site together with the neighbouring adenomyotic foci for estrogen receptors, aromatase, p53 and COX-2 expression when compared to the distant adenomyotic glands and the endometrium.
  • CONCLUSION: Adenocarcinoma in adenomyosis may be affected by local hormonal influence and, despite its small size, may metastasize.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenomyoma / pathology. Endometrial Neoplasms / pathology. Leiomyoma / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Obstet Invest. 1999;48 Suppl 1:21-8 [10559661.001]
  • [Cites] Am J Obstet Gynecol. 1961 Aug;82:408-16 [13766580.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):18-22 [11006024.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):308-13 [11350616.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):239-45 [12068169.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] Am J Reprod Immunol. 2002 Jul;48(1):50-6 [12322896.001]
  • [Cites] Hum Reprod. 2002 Oct;17(10):2725-36 [12351554.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):406-8 [15005792.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 2004 Apr;33(2):140-4 [15052180.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):94-8 [15068832.001]
  • [Cites] Semin Reprod Med. 2004 Feb;22(1):51-60 [15083381.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):1004-6 [15361215.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):483-8 [15863148.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 May;95(1-5):57-62 [16024248.001]
  • [Cites] Hum Reprod Update. 2006 Jan-Feb;12(1):49-56 [16123052.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Jan 1;124(1):101-5 [16456945.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2376-85 [16710036.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1673-8 [16884383.001]
  • [Cites] Maturitas. 2007 Feb 20;56(2):190-7 [16963204.001]
  • [Cites] Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):827-32 [7446615.001]
  • [Cites] Obstet Gynecol. 1986 Jan;67(1):145-8 [3940328.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(4):265-71 [8236823.001]
  • [Cites] Eur J Gynaecol Oncol. 1994;15(6):418-23 [7875156.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):241-6 [8751556.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12):4474-80 [9851796.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):141-4 [10461008.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):379-88 [10786803.001]
  • (PMID = 17584489.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; EC 1.14.14.1 / Aromatase; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC1913924
  •  go-up   go-down


75. Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA, Hellenic Co-operative Oncology Group: Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecol Oncol; 2008 Jul;110(1):87-92
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
  • OBJECTIVE: Taxanes, anthracyclines, and platinum compounds represent the chemotherapeutic agents with the greatest activity in metastatic endometrial carcinoma.
  • We administered the combination of paclitaxel, epirubicin and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity.
  • CONCLUSIONS: The combination of paclitaxel, epirubicin and carboplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Epirubicin / administration & dosage. Female. Greece. Humans. Injections, Intravenous. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Patient Selection. Recurrence

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455782.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


76. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


77. Ohta Y, Hamatani S, Suzuki T, Ikeda K, Kiyokawa K, Shiokawa A, Kushima M, Ota H: Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression. Pathol Res Pract; 2008;204(9):677-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising from a giant cystic adenomyosis: a case report with immunohistochemical analysis of laminin-5 gamma2 chain and p53 overexpression.
  • We report a case of a clear cell adenocarcinoma arising from a giant cystic adenomyosis, with immunohistochemical analysis of p53 and laminin-5 gamma2 chain overexpression.
  • Microscopically, not only clear cell adenocarcinoma showing myometrial invasion but also single-layered clear cell adenocarcinoma cells lining the cyst wall were observed.
  • Although the tumor cells within the uterus showed a low positive cell ratio for p53, the metastatic foci showed a remarkable p53 overexpression.
  • Laminin-5 gamma2 chain expression was low in papillary proliferation and high in myometrial invasion and metastatic foci.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Laminin / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467037.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LAMC2 protein, human; 0 / Laminin; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


78. Alrahwan D, Staerkel G, Gong Y: Fine needle aspiration cytology of a metastatic duct carcinoma of the prostate: a case report. Acta Cytol; 2006 Jul-Aug;50(4):469-72
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a metastatic duct carcinoma of the prostate: a case report.
  • BACKGROUND: Prostatic ductal carcinoma (PDC) is a rare variant of prostatic adenocarcinoma.
  • Without proper clinical information, a fine needle aspiration (FNA) diagnosis of metastatic PDC can be challenging as this tumor can morphologically mimic adenocarcinomas from other sites.
  • To our knowledge, FNA findings of metastatic PDC have not been previously reported.
  • Cell block sections revealed tumor cells forming tubulopapillary architecture lined with tall columnar cells with focal nuclear pseudostratification, reminiscent of uterine endometrial carcinoma.
  • CONCLUSION: Because of the rarity and nonspecific cytomorphologic characteristics of this tumor, clinical history, radiologic findings and a high index of suspicion in conjunction with ancillary studies are important in achieving a correct FNA diagnosis of metastatic PDC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901017.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Cozad SC: Stage II adenocarcinoma of the endometrium: adjuvant radiotherapy and recurrence patterns. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):205-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II adenocarcinoma of the endometrium: adjuvant radiotherapy and recurrence patterns.
  • PURPOSE: Review patterns of recurrence for Stage II endometrial cancer in a community practice.
  • METHODS AND MATERIALS: A retrospective review of patients with endometrial cancer diagnosed between 1985-2002.
  • Five-year actuarial vaginal, pelvic sidewall/nodal, and metastatic control rates were 100% and 100%, 96.9% and 100%, and 79% and 84.2% for patients receiving EBRT or EBRT with brachytherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164851.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Bigsby GE 4th, Holloway RW, Weppelman B, Reynolds RB, Williams B: Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up. Gynecol Oncol; 2005 Apr;97(1):256-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up.
  • BACKGROUND: There are few reported cases of cardiac metastasis associated with endometrial cancer (EC) and no reports of long-term survival.
  • She underwent exploration of the heart with debulking which revealed a metastatic poorly differentiated epithelial tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790471.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Besirli CG, Comer GM: High-resolution OCT imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging; 2010 Nov-Dec;41 Suppl:S96-S100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bilateral diffuse uveal melanocytic proliferation was diagnosed based on these clinical findings, and a systemic evaluation for malignancy revealed metastatic endometrial adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Aged. Biopsy, Needle. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiography. Female. Fluorescein Angiography. Functional Laterality. Humans. Lymphatic Metastasis. Lymphography. Subretinal Fluid. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 21117612.001).
  • [ISSN] 1938-2375
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Davidson B, Dong HP, Holth A, Berner A, Risberg B: The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. Breast J; 2008 Sep-Oct;14(5):476-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions.
  • Comparative analysis of breast carcinoma effusions with previously studied ovarian and cervical/endometrial adenocarcinomas (ACs) showed significantly higher CXCR4 expression in breast carcinoma cells compared to the other gynecological ACs (p = 0.001).
  • Breast and cervical/endometrial carcinoma effusions showed different expression of chemokine receptors in lymphocytes (lower CXCR1, higher CXCR4 and CCR7 levels; p = 0.012, p = 0.005, p < 0.001, respectively) and macrophages (higher CCR7 levels; p < 0.001), as well as lower CD8 counts (p < 0.001) and higher CD19 counts (p = 0.001) compared to ovarian carcinoma effusions.
  • In conclusion, breast carcinoma cells express CXCR4, a unique feature among metastatic ACs in effusions, with rare expression of other chemokine receptors.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Receptors, CXCR4 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657145.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, CXCR4
  •  go-up   go-down


83. Pozharisskiĭ KM, Samsonova EA, Ten VP, Maksimova NA, Urmancheeva AF: [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value]. Arkh Patol; 2005 Mar-Apr;67(2):13-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
  • Expression of the above markers is of essential value together with metastatic involvement of regional lymph nodes, stage of the disease and pathogenetic variant for determining prognosis of carcinoma aggressiveness and disease outcome.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ki-67 Antigen / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938112.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


84. Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS: Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med; 2007;5:15
Hazardous Substances Data Bank. YTTRIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.
  • BACKGROUND: Treatment records and follow-up data on 40 patients with primary and metastatic liver malignancies who underwent a single whole-liver treatment with Y-90 resin microspheres (SIR-Spheres Sirtex Medical, Lake Forest, IL) were retrospectively reviewed.
  • RESULTS: Of the 40 patients, 5 had hepatocellular cancer (HCC), and 35 had metastatic liver tumors (15 colorectal cancer, 10 neuroendocrine tumors, 4 breast cancer, 2 lung cancer, 1 ovarian cancer, 1 endometrial cancer, and 2 unknown primary adenocarcinoma).

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2000 Oct;41(10):1673-81 [11037997.001]
  • [Cites] Phys Med Biol. 2001 Feb;46(2):487-98 [11229728.001]
  • [Cites] Arch Surg. 2007 Jul;142(7):675-82 [17638807.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1209-11 [16818957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):333-7 [11379303.001]
  • [Cites] Ann Oncol. 2001 Dec;12(12):1711-20 [11843249.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):815-20 [12029557.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] J Vasc Interv Radiol. 2004 Apr;15(4):335-45 [15064336.001]
  • [Cites] Jpn J Clin Oncol. 2004 Sep;34(9):532-9 [15466827.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Aug;124(4):596-9 [1163723.001]
  • [Cites] J Surg Oncol. 1978;10(4):327-36 [692139.001]
  • [Cites] Arch Pathol Lab Med. 1980 Nov;104(11):584-8 [6893535.001]
  • [Cites] J Surg Oncol. 1982 Jul;20(3):151-6 [7201051.001]
  • [Cites] Radiology. 1989 Sep;172(3):857-60 [2549567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):619-23 [2318695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):463-7 [2061122.001]
  • [Cites] Aust N Z J Surg. 1992 Feb;62(2):105-10 [1586298.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):70-3 [8271063.001]
  • [Cites] Br J Radiol. 1994 Feb;67(794):136-9 [8130973.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):994-9 [7947110.001]
  • [Cites] Br J Radiol. 1997 Aug;70(836):823-8 [9486047.001]
  • [Cites] J Surg Oncol. 2004 Nov 1;88(2):78-85 [15499601.001]
  • [Cites] Arch Surg. 1964 Aug;89:244-9 [14160151.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Jan;93:200-8 [14243011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63 [15590187.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):205-13 [15713921.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jul;16(7):911-35 [16002500.001]
  • (PMID = 17359531.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Toll-Like Receptors; 0 / Yttrium Radioisotopes; 58784XQC3Y / Yttrium
  • [Other-IDs] NLM/ PMC1845138
  • [General-notes] NLM/ Original DateCompleted: 20070802
  •  go-up   go-down


85. Camerini A, Rondini M, Garrone O, Valsuani C, Donati S, Siclari O, Sgambato A, Tartarelli G, Vincenti M, Mattiot VP, Porta RP, Puccetti C, Puccinelli P, Amoroso D: Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biol Ther; 2009 Aug;8(15):1450-5
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients.
  • All coagulation indices and mean endometrial mucosa thickness value did not vary.
  • Endometrial mucosa thickness was evaluated before fulvestrant administration and at end-study time.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Agents, Hormonal / pharmacology. Breast Neoplasms / drug therapy. Cholesterol / blood. Estradiol / analogs & derivatives. Estrogen Receptor Modulators / pharmacology. Estrogens. Neoplasm Proteins / analysis. Neoplasms, Hormone-Dependent / secondary. Progesterone. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Aromatase Inhibitors / pharmacology. Aromatase Inhibitors / therapeutic use. Cholesterol, LDL / blood. Endometrium / drug effects. Endometrium / ultrastructure. Female. Humans. Lipid Metabolism / drug effects. Middle Aged. Postmenopause. Prospective Studies. Triglycerides / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Aug;8(15):1456-8 [19617703.001]
  • (PMID = 19556864.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Cholesterol, LDL; 0 / Estrogen Receptor Modulators; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Triglycerides; 22X328QOC4 / fulvestrant; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


86. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • RESULTS: A woman presenting with postmenopausal bleeding and abdominal distantion was assessed by endometrial biopsy and explorative surgery.
  • Furthermore, the focal endometrial irregularity at the left uterine cornus turned out to be a well differentiated endometrial carcinoma of the endometrioid type with <1/3 myometrial invasion.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • DISCUSSION: When compared with patients having metastatic lesions, most synchronous female malignancies are accompanied with early stage and low-grade with a more favorable prognosis.
  • However, there is paucity of data for the exact criterion to distinguish primary tumors from metastatic lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066567.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


88. Mylonas I: Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep; 2010 Aug;24(2):385-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human endometrial cancer expresses both the known estrogen receptors (ER-alpha and ER-beta).
  • The significance of the relative expression of both ER subtypes in endometrial adenocarcinomas remains to be clarified and the usefulness of the determination of the receptor status in endometrial cancer patients is still controversially discussed.
  • Pathological and surgical records of 214 patients who were diagnosed with an endometrioid adenocarcinoma without other histological types (including mucinous, mixed, squamous or villoglandular differentiation) were reviewed for both estrogen receptors.
  • The loss of receptor positivity for ER-alpha resulted in a poorer cause-specific survival in endometrial cancer patients, while ER-beta did not affect survival.
  • Interestingly, metastatic patients who expressed ER-alpha or ER-beta had a better survival outcome than estrogen receptor negative patients.
  • However, ER-alpha and ER-beta were not independent factors with survival in endometrial adenocarcinoma patients.
  • Therefore, the analysis of both estrogen receptors might be used as a marker to identify high-risk patients only in a subset of patients with endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596625.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta
  •  go-up   go-down


89. Horn LC, Hänel C, Bartholdt E, Dietel J: Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types. Int J Gynecol Pathol; 2006 Jul;25(3):247-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types.
  • We report a serous carcinoma of the endometrium with a choriocarcinomatous component and review of the literature.
  • Postoperatively, the patient developed diffuse pulmonary metastatic disease.
  • The first one is morphologically and clinically more related to the gestational choriocarcinoma with strongly elevated serum hCG levels, early onset of (distant) metastatic disease, and consecutively rapid and often fatal clinical course.
  • The second type presents as an endometrial carcinoma with single syncytiotrophoblast-like cells, associated with low serum hCG, no distant metastatic disease, and, consequently, a better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810062.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 14
  •  go-up   go-down


90. Asensio N, Luis A, Costa I, Oliveira J, Vaz F: Meningeal carcinomatosis and uterine carcinoma: three different clinical settings and review of the literature. Int J Gynecol Cancer; 2009 Jan;19(1):168-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Leptomeningeal carcinomatosis is a rare metastatic event in gynecological neoplasias, and most cases occur in ovarian cancer.
  • It is extremely infrequent in cervical cancer, and so far, there are not any reports of this complication in association with endometrial cancer.
  • PATIENTS AND METHODS: We report a case of leptomeningeal carcinomatosis secondary to endometrial carcinoma and 2 complex cervix cancer cases.
  • The case we report of endometrial carcinoma, unique in the literature, is a serous adenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Meningeal Neoplasms / secondary. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258961.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


91. Azueta A, Gatius S, Matias-Guiu X: Endometrioid carcinoma of the endometrium: pathologic and molecular features. Semin Diagn Pathol; 2010 Nov;27(4):226-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the endometrium: pathologic and molecular features.
  • Endometrioid carcinoma of the endometrium is the most common type of endometrial carcinoma.
  • The microscopic appearance of the tumor resembles that of the proliferative endometrium, with a variable degree of glandular complexity and cellular pleomorphism.
  • The main differential diagnosis includes endocervical adenocarcinoma, atypical polypoid adenomyoma, malignant mixed Müllerian tumors, and metastatic tumors to the endometrium.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309258.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


92. Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IeM, Davidson B: The diagnostic role of claudins in serous effusions. Am J Clin Pathol; 2007 Jun;127(6):928-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the diagnostic role of claudins in effusion cytology in 325 effusions, including 218 ovarian, 49 breast, 15 cervical or endometrial, 10 gastrointestinal, and 8 lung adenocarcinomas and 25 malignant mesotheliomas (MMs).
  • Ovarian and breast adenocarcinoma were further analyzed for claudin-7 expression.
  • Claudin-1 expression was most frequent in ovarian and cervical or endometrial adenocarcinoma compared with other adenocarcinomas and MMs (P < .001).
  • Claudin-7 expression was higher in ovarian than in breast adenocarcinoma (P < .001).
  • Our data suggest that expression of claudin-3 or claudin-7 is specific for adenocarcinoma and rules out the diagnosis of cells as mesothelial and that absence of claudin-1 expression excludes ovarian carcinoma as the possible origin of metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascitic Fluid / pathology. Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Pleural Effusion, Malignant / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509990.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


93. Groisman GM, Bernheim J, Halpern M, Brazowsky E, Meir A: Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum. Arch Pathol Lab Med; 2005 Jul;129(7):920-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All secondary tumors were diagnosed through endoscopic biopsies and included 8 cases of ovarian (4 serous, 2 mucinous, and 2 endometrioid), 6 of mammary (4 lobular and 2 ductal), 4 of gastric (2 intestinal and 2 diffuse), 4 of pulmonary, 4 of pancreatic (ductal), 3 of prostatic, 3 of colorectal, and 2 of endometrial origin.
  • RESULTS: Cdx2 was expressed in normal colorectal epithelium, in primary colorectal adenocarcinomas (20/20 cases), in secondary adenocarcinomas of colorectal (3/3) and gastric (3/4) origin, and in metastatic ovarian mucinous adenocarcinomas (2/2).
  • In contrast, no Cdx2 immunoreactivity was observed in secondary colorectal tumors of ovarian (serous and endometrioid), mammary, pancreatic, pulmonary, prostatic, and endometrial origin.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / secondary. Gene Expression Regulation, Neoplastic / genetics. Homeodomain Proteins / genetics
  • [MeSH-minor] Breast Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Humans. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / pathology. Prostatic Neoplasms / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15974817.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


94. Miyamoto H, Jones CE, Raymond DP, Wandtke JC, Strang JG, Bourne PA, Bonfiglio TA, Xu H: Pulmonary metastases from uterine neoplasms after long tumour-free interval: four cases and review of the literature. Pathology; 2009;41(3):234-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1 was a 68-year-old woman who had three pulmonary nodules 23 years after hysterectomy for low-grade endometrial stromal sarcoma (LGESS).
  • The nodules obtained with video-assisted thoracic surgeries were consistent with metastatic LGESS.
  • Case 3 was a 77-year-old woman who had a large lung mass with satellite nodules 17 years after hysterectomy with bilateral salpingo-oophorectomy and subsequent radiotherapy for endometrial endometrioid adenocarcinoma (EEA).
  • The biopsied and resected lung tumour was consistent with metastatic EEA.
  • Case 4 was a 51-year-old woman who underwent total hysterectomy and subsequent radiotherapy for endocervical adenocarcinoma 12 years ago and lung lobectomy for metastatic disease 8 years ago.
  • She then developed two pulmonary lesions 14 months ago, and these resected after radiotherapy were metastatic endocervical adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Leiomyoma / pathology. Lung Neoplasms / secondary. Sarcoma, Endometrial Stromal / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291535.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 41
  •  go-up   go-down


95. Paszkiewicz-Gadek A, Porowska H, Pietruczuk M, Haczynski J, Kisiel DG, Wolczynski S: Effect of estradiol and raloxifene on MUC1 expression and adhesive properties of Ishikawa cells. Oncol Rep; 2005 Aug;14(2):583-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steroid regulation of MUC1 gene expression is essential, since overexpression of MUC1 may influence the metastatic potential of cancer cells.
  • Our earlier results demonstrated that tamoxifen, alone and combined with estradiol, inhibits MUC1 biosynthesis in endometrial adenocarcinoma cells, in contrast to estradiol.
  • Therefore, raloxifene, which stimulates MUC1 expression in cancer cells and inhibits their adhesion to collagen to a lesser degree than estradiol, may be a clinically safe treatment for the endometrium.
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antigens, CD29 / metabolism. Cell Adhesion / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Epitopes / metabolism. Estrogen Antagonists / pharmacology. Female. Flow Cytometry. Humans. Integrin alpha2 / immunology. Integrin alpha2 / metabolism. Polysaccharides / metabolism

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. RALOXIFENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012748.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD29; 0 / Epitopes; 0 / Estrogen Antagonists; 0 / Integrin alpha2; 0 / Mucin-1; 0 / Polysaccharides; 4F86W47BR6 / Raloxifene Hydrochloride; 4TI98Z838E / Estradiol
  •  go-up   go-down


96. Burbos N, Giarenis I, Ostrowski J, Lonsdale R, Nieto JJ: Synchronous diagnosis of multiple tumours in a postmenopausal woman. Arch Gynecol Obstet; 2009 Oct;280(4):627-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology showed a Grade 3 endometrial adenocarcinoma.
  • Both ovaries were completely replaced by partially necrotic poorly differentiated endometrioid adenocarcinoma.
  • Small deposits of metastatic adenocarcinoma were seen within the omentum.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Genital Neoplasms, Female / diagnosis. Liposarcoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19198863.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


97. Clavero JM, Deschamps C, Cassivi SD, Allen MS, Nichols FC 3rd, Barrette BA, Larson DR, Pairolero PC: Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg; 2006 Jun;81(6):2004-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 103 patients, 70 of whom had metastatic disease limited to the lungs.
  • The primary tumor originated in the uterine corpus in 37 patients, endometrium in 23, cervix in 7, ovaries in 2, and vagina in 1.
  • Histopathology was leiomyosarcoma in 29 patients, adenocarcinoma in 23, other sarcoma in 11, squamous cell carcinoma in 5, and choriocarcinoma and endolymphatic stromal myosis in 1 each.
  • CONCLUSIONS: Pulmonary resection for metastatic gynecologic cancer in selected patients is safe and effective.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Choriocarcinoma / mortality. Choriocarcinoma / secondary. Choriocarcinoma / surgery. Choriocarcinoma / therapy. Combined Modality Therapy. Disease-Free Survival. Endometrial Stromal Tumors / mortality. Endometrial Stromal Tumors / secondary. Endometrial Stromal Tumors / surgery. Endometrial Stromal Tumors / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Leiomyosarcoma / mortality. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Leiomyosarcoma / therapy. Life Tables. Lymph Node Excision. Middle Aged. Ovarian Neoplasms / mortality. Ovarian Neoplasms / therapy. Ovariectomy. Postoperative Complications / mortality. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sarcoma / mortality. Sarcoma / secondary. Sarcoma / surgery. Sarcoma / therapy. Survival Analysis. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / therapy. Vaginal Neoplasms / mortality. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731120.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Kumar N, Bongiovanni M, Molliet MJ, Pelte MF, Egger JF, Pache JC: Diverse glandular pathologies coexist with high-grade squamous intraepithelial lesion in cyto-histological review of atypical glandular cells on ThinPrep specimens. Cytopathology; 2009 Dec;20(6):351-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Thirty-nine ThinPrep cervical smear (Pap) tests reported as AGC of undetermined significance and showing high-grade lesions on histology [cervical intraepithelial neoplasia (CIN) 2 or 3, endometrial or extrauterine adenocarcinoma] were reviewed retrospectively to identify the cases of high-grade squamous intraepithelial lesion with endocervical glandular extension, using the Bethesda 2001 system.
  • This included endocervical glandular extension in 63%, benign glandular pathology in 33% and pre-neoplastic or malignant glandular pathology (endocervical glandular dysplasia, adenocarcinoma in situ and metastatic breast carcinoma) in 17% cases.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Retrospective Studies. Sensitivity and Specificity. Young Adult


99. Akbulut M, Tosun H, Soysal ME, Oztekin O: Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. Arch Gynecol Obstet; 2008 Jul;278(1):79-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature.
  • OBJECTIVE: An endometrioid adenocarcinoma (EAC) with true trophoblastic differentiation is a rare event with a highly aggressive clinical course.
  • CASE: We report an endometrioid adenocarcinoma of the endometrium in which there was a morphologically conventional-appearing EAC component admixed with multinucleated giant cells and large pleomorphic tumor cells that resembled a choriocarcinoma without an elevated serum level of human chorionic gonadotropin (hCG) in a 42-year-old unmarried woman with a history of abnormal uterine bleeding.
  • Histopathologic study of the specimen showed endometrioid adenocarcinoma extended to the deep myometrium with a focus of hemorrhagic and necrotic tumor composed of multinucleated giant cells, large pleomorphic tumor cells, suggesting choriocarcinomatous differentiation (CD).
  • A complete clinical workup ruled out metastatic spread to the brain, lungs, skeleton, or abdomen.
  • CONCLUSION: Although endometrioid adenocarcinoma with choriocarcinomatous differentiation is known to behave in a more aggressive course, this disease may have a good prognosis with a clinically indolent course when it is small, and without elevated serum hCG levels.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 24
  •  go-up   go-down


100. Voglmayr E, Widder J: [Who makes decisions--the dilemma of decision-making within the framework of job-sharing in a hospital]. Wien Med Wochenschr; 2006 May;156(9-10):314-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At first she refused postoperative chemotherapy, but then returned with a very advanced state of metastatic growth.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Communication. Decision Making. Endometrial Neoplasms / therapy. Interprofessional Relations. Neoplasms, Multiple Primary / therapy. Ovarian Neoplasms / therapy. Palliative Care / methods. Patient Care Team. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830254.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down






Advertisement